Vera Therapeutics, Inc. (VERA) stock intrinsic value fair value estimate & owner earnings analysis

Vera Therapeutics is a one-product biotechnology company based in Brisbane, California. Its drug, TRUTAKNA (atacicept), is a once-weekly self-injected medicine for IgA nephropathy, a chronic kidney disease. It blocks two immune signals, BAFF and APRIL. The FDA granted accelerated approval on July 7, 2026 to reduce protein in the urine in adults at risk of disease progression. On September 15, 2026 the company reported the final two-year results of its ORIGIN 3 trial: every prespecified endpoint was met, kidney function (eGFR) declined about 5.0 points a year less than on placebo, and the risk of the composite kidney-progression endpoint fell 76%. Vera plans to file for full approval in the fourth quarter of 2026. It has never had a profitable year. Owner earnings (operating cash flow excluding working-capital swings, minus stock compensation and capital spending) were -$30 million in 2021, -$86 million in 2022, -$101 million in 2023, -$162 million in 2024 and -$304 million in 2025, or -$4.73 per share. None of those years describes the business as it is now, a company with an approved drug, so we built the value from the economics of TRUTAKNA itself rather than from a historical average. The facts we used are these. The list price is $425,000 a year. The company reported more than 350 patient start forms in the first ten weeks after approval, along with early paid insurance claims; no sales figure has been reported yet. Vera licenses atacicept from Ares Trading, an affiliate of Merck KGaA. It owed Ares $20 million on US approval and pays royalties in the low double digits to mid-teens on sales, plus sales milestones of up to $515 million that begin with $15 million at $250 million of annual sales and $50 million at $500 million. Costs in the second quarter of 2026 ran at about $450 million a year: research $60.1 million and general and administrative costs, which include the launch, $52.4 million for the quarter, including stock compensation. As a biologic, the drug has 12 years of US market exclusivity from approval, to about mid-2038. The licensed issued patents expire between 2027 and 2029, and newer patent applications are not yet granted, so we give no value beyond 2038. Profits fade to zero by 2041 as biosimilar competition arrives. The market is crowded. The filing names approved rivals from Otsuka (VOYXACT, an anti-APRIL antibody with a $390,000 list price), Novartis (two drugs), Travere and Asahi Kasei, and late-stage programs at Roche/Ionis, Vertex, AstraZeneca, Biogen, Takeda and Novartis. Our judgements: we assume a 20% discount from list to net price, that 60% of start forms become patients who stay on therapy, and that costs stay at the second-quarter 2026 level. Tax losses of about $390 million plus the losses still to come shelter early profits; after that we apply a 21% tax. We give no value to other diseases Vera is studying (primary membranous nephropathy, FSGS, minimal change disease) or to its earlier-stage programs, because none has approval or sales. The cases differ only in how long the demand seen so far lasts. Base case: new patients arrive at the pace of the first ten weeks (about 1,800 start forms a year) for two years after approval. After that, new starts only replace patients who stop. That gives about 2,160 patients on therapy and roughly $730 million of annual sales from 2029. The business loses about $190 million in the second half of 2026 and about $170 million in 2027, then earns about $120 million to $150 million a year until exclusivity ends. For comparison, owner earnings fell from -$162 million in 2024 to -$304 million in 2025. The first forecast year (2027) is an improvement, and the reason is dated: approval on July 7, 2026 turned a company with no product sales into a selling one. The business is worth about $680 million. Bear case: the start-form pace lasts only one year, to about 1,080 patients and $370 million of sales, which does not cover the current cost base. The company burns about $205 million more in 2027 and then has to cut costs until the drug merely breaks even. The business is worth about -$383 million, which is the cash it consumes before breaking even. Bull case: the launch pace holds for four years, to about 4,300 patients and $1.47 billion of annual sales by 2031. Royalties are at the top of the range, and we charge the full remaining $450 million of sales milestones. The business is worth about $3.26 billion. Balance sheet: at June 30, 2026 Vera held $499.2 million of cash and short-term securities. It owes $75 million to Oxford Finance under a facility that allows up to $500 million. The loan is interest-only until August 2029 and matures in June 2030. It carries floating interest of the higher of one-month SOFR or 3.75%, plus 4.95%, and a 5% final fee. We count it at about $85 million, including the final fee and the extra cost of interest above 6%. After the loan and the $20 million approval milestone owed to Ares, net cash is about $394 million. Per share: bear, -$383M + $394M = about $11 million, or $0.15 per share on 72.1 million shares. The cash left roughly equals the loan, so shareholders would be left with close to nothing and would need new money to continue. Base, $680M + $394M = $1.07 billion, or $12.75 per share. Bull, $3.26B + $394M = $3.65 billion, or $43.36 per share. The base and bull cases count all 84.2 million shares, including about 12.1 million shares of stock options and other awards. Neither case needs new equity: base-case cash falls to about $100 million at the low point in 2027, before the business turns positive. The loan carries two financial covenants and a material-adverse-change default clause, which matter in the bear case. What would make this wrong: the start-form count is a single ten-week figure from the company and is not yet confirmed by reported revenue, and the net price and persistence rates are our estimates. If the launch pace continues longer than two years, the value is well above the base case. If rivals priced below TRUTAKNA hold their ground, it moves toward the bear case. Because the valuation rests on sales not yet reported, the margin-of-safety price applies only after filed results confirm roughly the base-case pace. At that point the margin-of-safety price of $6.50, about half the base value, allows for a single product in a crowded field with a fixed exclusivity end date.